UCB presented new clinical data from studies of CIMZIA (certolizumab pegol) at the 2015 European League Against Rheumatism Annual Congress in Rome, Italy. The data showed CIMZIA's efficacy in treating adults with severe active axial spondyloarthritis, active psoriatic arthritis, and moderate to severe rheumatoid arthritis. UCB also released the first data from Phase 3 trials evaluating the safety and efficacy of using CIMZIA in combination with optimized methotrexate.

1. UCB Presents New Clinical Data
at EULAR 2015
By Anna Richo

2. Introduction
• An experienced attorney with expertise in the
pharmaceutical industry, Anna Richo previously held
executive legal positions with such companies as Amgen
Inc. and Baxter Healthcare Corporation. Anna Richo
currently draws on more than 25 years of legal
experience to serve as the executive vice president and
general counsel of the biopharmaceutical firm UCB in
Brussels, Belgium.
In a recent press release, UCB announced that it
sponsored a number of presentations on various
rheumatic diseases at the June 2015 European League
Against Rheumatism Annual Congress (EULAR) in
Rome, Italy.

3. EULAR 2015
• At EULAR,the company discussed its most recent
research on CIMZIA® (certolizumab pegol) and its
efficacy in treating adults with severe active axial
spondyloarthritis, active psoriatic arthritis, and
moderate to severe rheumatoid arthritis.
During the presentations, UCB released data from its
investigational immunology pipeline, highlighting the
company’s commitment to improving the quality of life
for individuals with serious diseases. The company also
delivered the first investigational data from Phase 3 of
the trials, evaluating the safety and efficacy of using
CIMZIA in coordination with optimized methotrexate.